C884FB38-DE5C-48BA-95F1-4ABD2991E833
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.501971090670171
- age_years
- 54
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.541
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.471
- APOPTOSIS+0.422
- XENOBIOTIC_METABOLISM+0.409
- INTERFERON_ALPHA_RESPONSE+0.393
- FATTY_ACID_METABOLISM+0.388
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.386
- ADIPOGENESIS+0.385
- DNA_REPAIR+0.372
- INTERFERON_GAMMA_RESPONSE+0.349
Top 10 suppressed
- MITOTIC_SPINDLE-0.352
- G2M_CHECKPOINT-0.311
- SPERMATOGENESIS-0.183
- E2F_TARGETS-0.165
- HEDGEHOG_SIGNALING-0.155
- KRAS_SIGNALING_DN-0.153
- ANDROGEN_RESPONSE-0.003
- PROTEIN_SECRETION+0.003
- UV_RESPONSE_DN+0.010
- APICAL_JUNCTION+0.029
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 65DAB913-D39C-4AC4-BB1C-10E58914571F | — | — | 0.908 |
| 2 | SRR3147741 | — | — | 0.897 |
| 3 | 5B9D33F5-1B4F-4C06-A73A-CC723C1EF409 | — | — | 0.889 |
| 4 | 5B9DEC62-3DC7-4DE2-8B20-3E191594FCB4 | — | — | 0.881 |
| 5 | MNG919 | — | — | 0.880 |
| 6 | MDT-AP-2001 | Med | Medulloblastoma | 0.875 |
| 7 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.874 |
| 8 | TCGA-64-5781-01A-01R-1628-07 | — | cohortA4 | 0.866 |
| 9 | 6F4F72B3-E2B1-48DD-B9F4-C03AFCE79566 | — | — | 0.865 |
| 10 | 31550B35-DA39-4294-8368-811A412B2E3A | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.541 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.471 | Inavolisib | — uncovered |
| APOPTOSIS | 0.422 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.409 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.393 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.388 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.386 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.385 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.372 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.349 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.345 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.340 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.331 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.326 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.309 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.296 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.279 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.275 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.275 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |